decisionhealth Newsletters, Part B News - 2002 Issue 4 (April)
Ways and Means floats drug reimbursement policy
Subscribe or sign in to view the full article.
Article Overview
This article explains a proposed shift in Medicare reimbursement for drugs administered in physician offices, focusing on policy ideas discussed by congressional committees and related stakeholders. It compares the broad outlines of competing approaches to drug pricing and reimbursement, and it highlights why physician practice expenses, supplier contracting, and Medicare Part B payment policy are central to the discussion. The piece is relevant to physicians, oncology practices, coding and reimbursement professionals, and anyone tracking federal Medicare payment reform.
Why This Topic Matters
Changes to how Medicare pays for office-administered drugs can affect practice revenue, supplier relationships, and the way practice expenses are recognized. Readers who work in physician billing, reimbursement policy, or oncology practice management need to understand the direction of proposed federal changes and the organizations involved.
Article Sections
-
Proposed Medicare drug reimbursement policy
Introduces the committee proposal and explains the general Medicare payment issue being discussed for office-administered drugs.
-
Competitive billing model
Describes the broad structure of the proposed market-based contracting approach and the parties involved in supplying drugs to practices.
-
Alternative reimbursement approach
Summarizes a separate committee concept for drug payment that relies on manufacturer-reported pricing and congressional percentage settings.
-
Current pricing system and concerns
Reviews the existing reimbursement framework and the policy concerns raised about how drug payment levels are determined.
-
Committee negotiations and jurisdiction
Covers the legislative process, committee discussions, and jurisdiction questions surrounding the broader Medicare reform effort.
-
ASCO perspective on practice expenses
Highlights concerns from oncology stakeholders about practice expense recognition and the operational costs of administering drugs.
What You Will Learn
- How proposed Medicare drug reimbursement changes could affect physician practices
- What broad policy models are being discussed for office-administered drug payment
- Why practice expense recognition is a major issue in oncology reimbursement
- Which congressional committees and stakeholder groups are involved in the discussion
Who Should Read This
- Physicians
- Medical office administrators
- Billing and reimbursement professionals
- Oncology practice managers
- Health policy analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com